BTF3L4 Antibody

What is BTF3L4 and why is it important in research?

BTF3L4 (Basic Transcription Factor 3 Like 4) is a protein-coding gene that belongs to the NAC-beta family and contains a NAC-A/B domain. It plays crucial roles in transcriptional initiation and binds to polypeptide chains as they emerge from the ribosome, preventing their interaction with the signal recognition particle (SRP) . Recent research has identified BTF3L4 as a key factor in acetaminophen (APAP)-induced liver injury (AILI), where its overexpression mediates inflammatory responses and mitochondrial dysfunction . This association with liver pathology has elevated BTF3L4's importance as a potential diagnostic biomarker and therapeutic target.

When working with BTF3L4 antibodies, researchers should expect:

• Calculated molecular weight: 17 kDa (158 amino acids)

• Observed molecular weight in Western blot: 17-20 kDa

This information is critical for verifying antibody specificity and confirming detection of the correct protein . Any significant deviation from this expected molecular weight range may indicate non-specific binding or post-translational modifications.

What are the differences between polyclonal and monoclonal BTF3L4 antibodies?

Both types of BTF3L4 antibodies are commercially available with distinct characteristics:

Polyclonal BTF3L4 antibodies:

• Typically produced in rabbit

• Recognize multiple epitopes on the BTF3L4 protein

• Often provide stronger signals due to binding of multiple antibodies per target molecule

• Examples include antibodies targeting C-terminal (AA 111-140) or internal regions (AA 94-143)

Monoclonal BTF3L4 antibodies:

• Available from mouse hosts (e.g., clone 2G10)

• Recognize a single epitope on the BTF3L4 protein

• Provide consistent results between batches

• Useful when absolute specificity is required

The choice between polyclonal and monoclonal should be guided by experimental requirements and the specific research question .

What are the optimal fixation and antigen retrieval methods for BTF3L4 immunohistochemistry?

For optimal BTF3L4 detection in IHC applications:

Antigen retrieval recommendations:

• Primary method: TE buffer pH 9.0

• Alternative method: Citrate buffer pH 6.0

Fixation:

• Formalin fixation is compatible with BTF3L4 detection in paraffin-embedded tissue sections

Researchers should optimize these conditions for their specific tissue type and antibody, as antigen accessibility may vary between experimental contexts .

How should BTF3L4 antibodies be stored to maintain activity?

To preserve antibody functionality:

• Store at -20°C for long-term storage

• Some products remain stable for one year after shipment

• For liquid formulations containing glycerol (typically 50%), aliquoting may be unnecessary for -20°C storage

• For extended storage, addition of carrier protein (0.1% HSA or BSA) is recommended

• Avoid multiple freeze-thaw cycles

Most commercial BTF3L4 antibodies are supplied in buffer containing glycerol and preservatives such as sodium azide .

How can BTF3L4 antibodies be used to study APAP-induced liver injury?

BTF3L4 antibodies have proven valuable in studying the mechanisms of APAP-induced liver injury (AILI):

Experimental approaches:

• Immunohistochemistry/Immunofluorescence:

  • Detection of BTF3L4 overexpression in AILI model liver tissue sections

  • Co-localization with inflammatory markers and indicators of cell death

• Mechanistic studies:

  • Validation of BTF3L4 overexpression or knockdown models

  • Assessment of BTF3L4's impact on:

    • Apoptosis pathways

    • Reactive oxygen species generation

    • Inflammatory responses

    • Mitochondrial function

• Biomarker development:

  • Quantitative analysis of BTF3L4 expression in relation to AILI severity

  • Correlation with established markers of liver injury

Research has demonstrated that BTF3L4 expression is positively associated with inflammation in AILI, suggesting its potential as a diagnostic biomarker .

What controls should be used when working with BTF3L4 antibodies?

Robust experimental design requires appropriate controls:

Positive controls:

• Cell lines known to express BTF3L4 (HEK-293T, Jurkat cells)

• Tissues with confirmed BTF3L4 expression (brain tissue)

• Recombinant BTF3L4 protein

Negative controls:

• Primary antibody omission

• Non-specific IgG from the same host species

• BTF3L4 knockdown samples (shBTF3L4)

Technical validation:

• Western blot confirmation of single band at expected molecular weight (17-20 kDa)

• Titration of antibody dilutions to optimize signal-to-noise ratio

• Testing multiple antigen retrieval methods if applicable

How can researchers validate BTF3L4 antibody specificity?

Comprehensive validation should include:

• Protein expression analysis:

  • Western blot verification of a single band at the expected molecular weight (17-20 kDa)

  • Comparison of staining patterns across multiple validated antibodies targeting different epitopes

• Genetic approaches:

  • Compare staining in wild-type vs. BTF3L4 knockdown models

  • The research in result #1 describes lentiviral shRNA vectors for BTF3L4 knockdown that can serve as validation tools

• Peptide competition:

  • Pre-incubation of antibody with immunizing peptide should abolish specific staining

  • Several antibodies are generated using KLH-conjugated synthetic peptides from specific regions of BTF3L4

• Cross-species reactivity tests:

  • Verify specificity across species when working with non-human models

  • Available antibodies show reactivity with human, mouse, and rat BTF3L4

What primer sequences can be used for qPCR validation of BTF3L4 expression?

When correlating protein expression with transcript levels, researchers can use the following validated primer sequences for mouse BTF3L4:

• Forward: 5′-AGAAGGTGGTACATAGGACAGC-3′

• Reverse: 5′-CCGTGCCATCGTCTTTAATCAT-3′

For housekeeping gene control (mouse 18S):

• Forward: 5′-AGGGGAGAGCGGGTAAGAGA-3′

• Reverse: 5′-GGACAGGACTAGGCGGAACA-3′

These primers have been successfully used to validate BTF3L4 expression levels in liver injury research .

How can BTF3L4 be studied in relation to inflammatory pathways?

To investigate BTF3L4's role in inflammation, researchers can examine its relationship with key inflammatory markers:

Validated primer sequences for inflammatory markers:

• Mouse IL-1β forward: 5′-GAAATGCCACCTTTTGACAGTG-3′

• Mouse IL-1β reverse: 5′-TGGATGCTCTCATCAGGACAG-3′

• Mouse TNF-α forward: 5′-GATCGGTCCCCAAAGGGATG-3′

• Mouse TNF-α reverse: 5′-TTTGCTACGACGTGGGCTAC-3′

• Mouse MCSFR forward: 5′-GAAGCACCCTGACCACAAGA-3′

• Mouse MCSFR reverse: 5′-AGAGTGGGCCGGATCTTTGA-3′

Research has demonstrated that BTF3L4 expression positively correlates with inflammatory markers in AILI models, suggesting its potential role in regulating inflammatory responses .

How does BTF3L4 compare functionally to its paralog BTF3?

Understanding the relationship between BTF3L4 and its paralog BTF3 is essential for comprehensive functional studies:

Shared characteristics:

• Both are part of the NAC-beta family containing NAC-A/B domains

• Both involved in transcriptional initiation processes

• Both interact with nascent polypeptide chains emerging from ribosomes

Functional distinctions:

• BTF3 forms a stable complex with RNA polymerase IIB and is required for transcriptional initiation

• BTF3 has been better characterized in disease contexts, showing associations with various digestive cancers

• BTF3 downregulation induces mitochondrial dysfunction and intrinsic apoptosis in mouse liver cell lines

Research suggests that while both proteins share structural similarities, they may have distinct roles in disease contexts, with BTF3L4 specifically implicated in APAP-induced liver injury mechanisms .

How can discrepancies in BTF3L4 antibody staining patterns be resolved?

When faced with inconsistent results between different BTF3L4 antibodies:

• Compare epitope specificity:

  • Different antibodies target distinct regions of BTF3L4:

    • C-terminal region (AA 111-140)

    • Internal region (AA 94-143)

    • Various other epitopes

  • Epitope accessibility may be affected by protein conformation or interactions

• Optimize sample preparation:

  • Test multiple fixation protocols

  • Compare different antigen retrieval methods (TE buffer pH 9.0 vs. citrate buffer pH 6.0)

  • Adjust permeabilization conditions for intracellular staining

• Validate with complementary techniques:

  • Confirm protein expression with Western blotting

  • Correlate with mRNA expression using the validated primers

  • Consider proteomic approaches for absolute quantification

• Consider biological variables:

  • Expression levels may vary between tissues and experimental conditions

  • Post-translational modifications might affect epitope recognition

  • Protein interactions could mask specific epitopes

What are potential pitfalls in BTF3L4 expression analysis in disease models?

Researchers should be aware of several considerations when studying BTF3L4 in disease contexts:

• Expression dynamics:

  • BTF3L4 overexpression was identified as a pathogenic factor in AILI, but temporal dynamics need careful monitoring

  • Consider time-course experiments to capture expression changes

• Cell type heterogeneity:

  • Expression patterns may differ between cell types within a tissue

  • Consider single-cell approaches or co-staining with cell type-specific markers

• Model system limitations:

  • The AILI model in mice has demonstrated BTF3L4 overexpression

  • Validation in human samples is essential for translational relevance

  • Different injury models may show variable BTF3L4 regulation

• Technical artifacts:

  • Ensure antibody specificity through proper controls

  • Be aware of potential cross-reactivity with BTF3, its close paralog

  • Account for background staining in highly autofluorescent tissues like liver